Perrigo (NYSE:PRGO) has been given a $107.00 target price by research analysts at Cantor Fitzgerald in a research note issued on Sunday, December 10th. The firm presently has a “buy” rating on the stock. Cantor Fitzgerald’s target price suggests a potential upside of 22.97% from the company’s previous close.
PRGO has been the topic of a number of other research reports. Royal Bank of Canada raised Perrigo from an “underperform” rating to a “sector perform” rating and raised their target price for the company from $64.00 to $86.00 in a report on Friday, November 10th. Jefferies Group set a $71.00 price target on Perrigo and gave the company a “hold” rating in a research note on Sunday, October 29th. UBS Group reiterated a “buy” rating and issued a $98.00 price target (up from $84.00) on shares of Perrigo in a research note on Thursday, October 5th. CIBC began coverage on Perrigo in a research note on Thursday, September 7th. They issued an “outperform” rating and a $88.00 price target for the company. Finally, Deutsche Bank increased their price target on Perrigo from $88.00 to $95.00 and gave the company a “buy” rating in a research note on Thursday, September 14th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and nine have issued a buy rating to the company. Perrigo has a consensus rating of “Hold” and an average price target of $92.13.
Shares of Perrigo (NYSE:PRGO) traded down $0.17 during trading hours on Friday, reaching $87.01. The company had a trading volume of 415,300 shares, compared to its average volume of 1,671,347. The firm has a market capitalization of $12,280.00, a P/E ratio of -9.50, a P/E/G ratio of 1.86 and a beta of 0.64. Perrigo has a 1-year low of $63.68 and a 1-year high of $91.73. The company has a quick ratio of 1.24, a current ratio of 1.72 and a debt-to-equity ratio of 0.54.
In related news, EVP John Wesolowski sold 450 shares of the firm’s stock in a transaction on Thursday, December 7th. The stock was sold at an average price of $83.09, for a total transaction of $37,390.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Over the last ninety days, insiders have sold 1,051 shares of company stock valued at $89,810. 6.90% of the stock is owned by corporate insiders.
Several hedge funds have recently bought and sold shares of the company. Parametric Portfolio Associates LLC grew its stake in shares of Perrigo by 29.6% in the 3rd quarter. Parametric Portfolio Associates LLC now owns 229,115 shares of the company’s stock valued at $19,395,000 after buying an additional 52,361 shares during the period. Greenlight Capital Inc. grew its stake in shares of Perrigo by 14.8% in the 3rd quarter. Greenlight Capital Inc. now owns 2,901,032 shares of the company’s stock valued at $245,572,000 after buying an additional 374,032 shares during the period. Cetera Advisors LLC acquired a new stake in shares of Perrigo in the 3rd quarter valued at about $398,000. California Public Employees Retirement System boosted its stake in Perrigo by 3.9% during the 3rd quarter. California Public Employees Retirement System now owns 284,066 shares of the company’s stock valued at $24,046,000 after purchasing an additional 10,766 shares during the last quarter. Finally, Point72 Asset Management L.P. acquired a new position in Perrigo during the 3rd quarter valued at about $12,706,000. 83.32% of the stock is owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: “Perrigo (PRGO) Given a $107.00 Price Target at Cantor Fitzgerald” was published by American Banking and Market News and is owned by of American Banking and Market News. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this news story can be accessed at https://www.americanbankingnews.com/2017/12/25/perrigo-prgo-given-a-107-00-price-target-at-cantor-fitzgerald-3.html.
Perrigo Company Profile
Perrigo Company plc is a global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, animal health, dietary supplements, active pharmaceutical ingredients (API), and medical diagnostic products, and Multiple Sclerosis drug Tysabri.
